

Prevention & Treatment of Hepatitis and Chronic Liver Disease

Costa Mesa, CA – April 13, 2024

Conference Location	Hilton Orange County-Costa Mesa 3050 Bristol Street Costa Mesa, California 92626	Phone: (714) 540-7000 https://www.hilton.com/en/hotels/snacmhh-hilton-orange-county-costa-mesa
Parking at the Conference	Discounted Self-Parking of \$10,00 per day has been arranged for all participants. Please bring your parking ticket to the seminar registration desk to receive this rate	
Driving Directions	Follow I-405 N or S to Bristol Street in Costa Mesa. Continue on Bristol Street going West. Just before you reach Paularino Avenue, the hotel is on your left.	
Seminar Agenda and Syllabus Information	Registration begins at 7:30 a.m. in the Balboa Room. The Hepatitis and Chronic Liver Disease seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet or personal computer. Instructions to download the <i>App</i> will be provided. Wi-Fi will be available without charge.	
Pre-Program Activities	Pre-Lecture 1 – Viral Hepatitis –A summary for discovery and natural history of HCV 60 min Pre-Lecture 2 - End Stage Liver Disease: An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min	
7:30 am	Registration and View Exhibits	
8:00 am	Opening Comments and Pre-Test	
8:20 am	Advances in the Screening and Treatment of HCV <ul style="list-style-type: none"> Updates on diagnostic approaches Caring for At-risk populations – homeless, PWID, the incarcerated Novel FDA Approved Direct Acting Anti-virals Clinical Cases and Discussion 	
9:10 am	Hepatitis B: Epidemiology, History, Testing and Treatment <ul style="list-style-type: none"> The epidemiology of the Hepatitis B infection Efficacies and opportunities in HBV testing and vaccination The efficacy of HBV Vaccination and Anti-viral therapies of HBV HBV Re-activation and the Latest studies from EASL and AASLD 	
9:40 am	Delta Hepatitis and Hepatitis E Update <ul style="list-style-type: none"> Global and US perspective on the growth of Delta Hepatitis Lonafarnib and Bulevirtide of HDV: Benefits and potential hazards Testing and surveillance approaches Real world outcome studies on HDV and HEV 	
10:15 am	Break and View exhibits	
10:30 am	End Stage Liver Disease: Recap and Clinical Cases <ul style="list-style-type: none"> A review of Pre-course lecture on end-stage liver disease Complications of cirrhosis Liver transplant in the era of DAA's Clinical cases to illustrate HE. HRS and/or Thrombocytopenia 	

11:05 am	Hepatocellular Carcinoma(HCC) - Screening and Disease Progression <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Treatment and management options: Ablation, TACE and Surgery • New studies showing cost effectiveness of surveillance post SVR • PRIUS Study (MRI vs US) Abbreviated MRI • 2023 AASLD screening guidance for liver cancer and comments on biopsy for HCC
11:40 am	Hepatocellular Carcinoma: A case-based approach to New Systemic Treatment Options <ul style="list-style-type: none"> • Promising 1st and 2nd line therapies for liver cancer • New data on the benefit of downstaging • C chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC • Checkpoint inhibitors and VEGE inhibitors
12:20 pm	<i>Luncheon and Product Information Session</i>
12:55 pm	<i>Dessert and View Exhibits</i>
1:05 pm	Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis <ul style="list-style-type: none"> • Epidemiology of PSC and Ursodiol and Antibiotic Treatments • Causes and Markers of PBC • Coping with the clinical features of PBC • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid • Highlights of the ELATIVE study on elafibranor and the ENHANCE study on seladelpar
1:55 pm	Alcohol Associated Liver Disease <ul style="list-style-type: none"> • The growing prevalence of alcohol over-consumption and its impact on liver health • Alcohol consumption and malnutrition • Warning signs and intervention in alcohol-associated hepatitis • Promising therapeutic agents for AAH
2:30 pm	• <i>Break & View Exhibits</i>
2:45 pm	Steatotic Liver Disease: The new healthcare epidemic <ul style="list-style-type: none"> • New naming conventions for fatty liver disease: MASLD and MASH– what and why? • Epidemiology, Demographics and Diagnosis • Scoring, Staging and Management of Metabolic Liver Disease • The ‘unhealthy’ rise in MASLD in the US population and What can be done Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
3:20 pm	MASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies for NASH including Updates from AASLD and EASL • Lifestyle changes as a therapy • Drugs in clinical development for NASH – Semaglutide and Resmitemon • MASH Diagnosis and Treatment case
4:00 pm	Closing Comments, Post-test and Wrap-Up Program adjourns at 4:15 pm
Post-program activities	Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome 30 minutes Lecture 4 - Overcoming barriers to liver health in special populations - 30 minutes. Lecture 5 – AASLD Update – Highlights of the 2023 Liver Meeting – 30 minutes

Attendance Policies

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues, and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Information

Nurses - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1383. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)[™] organizations accredited by ACCME.


**TIMOTHY MORGAN, MD, FAASLD**

Dr. Timothy Morgan is Chief of Gastroenterology at the VA Long Beach Healthcare System and Professor of Medicine at the University of California, Irvine.

Dr. Morgan is the Director of the VA National Hepatitis C Resource Center which oversees programs to improve diagnosis and treatment of hepatitis C, and improve care for patients with cirrhosis, across the VA healthcare system. He is a co-chair of the AASLD-IDSA hepatitis C treatment guideline committee and chair of the VA HCV treatment guidelines. He has been an investigator on clinical trials in hepatitis C for the past 25 years, and in alcoholic hepatitis and alcoholic cirrhosis for the past 30 years. He is currently the Principal Investigator on the Southern California Alcoholic

Hepatitis Consortium, to evaluate new treatments and better understand the alcoholic hepatitis.

Dr. Morgan is a fellow of the American College of Physicians, American Gastroenterology Association, the American Association for the Study of Liver Disease

Your Seminar Faculty**BRIAN LEE, MD**

Dr. Lee is an adult hepatologist within the Digestive Health Institute at Hoag Health. He is triple board-certified in internal medicine, gastroenterology, and transplant hepatology. He practices in Newport Beach and Irvine with a focus on patient care in the diagnosis and treatment of complex liver diseases. His clinical interests include liver cancer, autoimmune liver diseases and alloimmune complications after liver transplantation.

Dr. Lee earned his medical degree from Rush Medical College at Rush University Medical Center in Chicago, Ill. and completed his residency in internal medicine and

fellowship in gastroenterology at the University of Southern California/LAC+USC and another fellowship in transplant hepatology at Icahn School of Medicine at Mount Sinai in New York.



TAMMY HARPER, NP-C Tammy Harper received her undergraduate degree at Union University in Tennessee and her Masters Degree in nursing from the University of California in Los Angeles. Tammy Harper joined the UCS Keck Scholl of Medicine team in 2013, after 14 years of practicing internal medicine. Her clinical interest and expertise are in chronic liver disease and liver transplantation. Tammy has participated in research studies related to Hepatitis C infections, including Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved Sustained Virologic Response to Direct Acting Antiviral Agents for Recurrent

Infection After Transplant